Arrowhead Pharmaceuticals, Inc. was represented by Gibson Dunn in concurrent public offerings of convertible notes, common stock, and pre-funded warrants to buy common stock for a total gross proceeds of $930 million, as well as capped call transactions pertaining to the convertible notes.